STOCK TITAN
  1. Home
  2. News
  3. BNGO

Bionano Genomics Inc - BNGO STOCK NEWS

Welcome to our dedicated news page for Bionano Genomics (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bionano Genomics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bionano Genomics's position in the market.

News
Bionano Announces 2024 Symposium: Four Consecutive Days of OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications
Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) announces its 2024 Symposium, a virtual event featuring OGM presentations by 27 customers worldwide. The event will showcase applications in cancer, cell and gene therapy, and constitutional genetic disease. Bionano will also unveil a new product to advance cytogenetics and structural variant analysis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.52%
Tags
none
-
News
Bionano Reports Preliminary Fourth Quarter and Full-Year 2023 Results
Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) reported unaudited preliminary financial and commercial highlights for Q4 2023. Revenue expected to be $10.4-10.7 million, a 27-30% increase over Q4 2022. Installed base of OGM systems increased by 36%, and nanochannel array flowcells sold expected to increase by 67% over Q4 2022. Full year 2023 revenue expected to be $35.8-36.1 million, a 29-30% increase over 2022. Cash, cash equivalents, and available-for-sale securities as of December 31, 2023, were approximately $102.8 million. The company achieved all full-year 2023 ELEVATE milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.23%
Tags
earnings
-
News
OGM Added to International System for Human Cytogenomic Nomenclature
Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) announced the addition of optical genome mapping (OGM) to the International System for Human Cytogenomic Nomenclature (ISCN). The OGM nomenclature is set to be published in the 2024 ISCN guide, providing a universal naming convention for genetic variants detected by OGM. This move is expected to enhance clear communication in publications and consistency in databases for genetic laboratories, marking a significant milestone for OGM and researchers using the workflow to advance molecular cytogenetics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.5%
Tags
none
News
International Consortium Publishes Comprehensive Roadmap for the Clinical Implementation of OGM in Hematological Malignancy Applications
Rhea-AI Summary
Bionano Laboratories (Nasdaq: BNGO) announced the publication of the first framework paper for the clinical adoption and implementation of the optical genome mapping (OGM) workflow for hematological malignancy applications. The framework was co-authored by an international consortium of 18 cancer researchers and is intended to help laboratories with the uniform adoption and implementation of an OGM workflow. It includes recommendations for laboratories planning to adopt OGM on topics such as assay development, clinical validation, implementation, algorithms for data interpretation, and strategies for efficient reporting. The framework paper outlines specific recommendations in three areas: validation, quality control, and analysis and interpretation of variants. Bionano Laboratories developed its laboratory developed test (LDT), marketed as OGM-Dx™ HemeOne, based on the process outlined in this publication.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.5%
Tags
none
-
News
Bionano Announces Significant Upgrades to its Bionano Solve Pipeline and its VIA™ Software for OGM Data Analysis in Constitutional Genetic Disease Research
Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) announced significant upgrades to its VIA™ software, enhancing the sensitivity and specificity for structural variation (SV) detection from optical genome mapping (OGM) data, further advancing OGM’s leadership in variant detection. The latest analysis pipeline, Bionano Solve 3.8.1, also enables comprehensive visualization, interpretation, and reporting of SVs and CNVs from OGM data in constitutional genetic disease research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
none
-
News
Bionano Announces Publication of Largest Prospective Prenatal Study Comparing OGM to Chromosomal Microarray Analysis and Karyotyping
Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) announced the results of a prospective prenatal study comparing optical genome mapping (OGM) to a combined workflow of chromosomal microarray analysis (CMA) and karyotyping (KT). OGM detected pathogenic structural variants in 20.5% of samples, outperforming CMA and KT in sensitivity, specificity, and positive predictive value. The study also revealed OGM's ability to identify novel pathogenic structural variants missed by traditional methods, showcasing its potential in prenatal diagnostics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.57%
Tags
none
News
Cancers Journal Publishes Special Issue Dedicated to OGM’s Impact on Hematological Malignancy Research
Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of a special issue of Cancers journal dedicated to the Company’s optical genome mapping (OGM) workflow. The issue features eight peer-reviewed publications, with three additional publications expected, covering the use of OGM in hematological malignancy research and demonstrating its potential to offer significant research insights. The guest editors describe the advantages OGM has over traditional cytogenetic methods and note that OGM offers benefits for laboratory adoption. The issue’s publications cover research indications including acute myeloid leukemia, chronic lymphocytic leukemia, myeloma, and myeloid cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.67%
Tags
none
-
News
Bionano Laboratories Announces Publication of the Analytical Validation of its OGM-Based Laboratory Developed Test for Hematological Malignancies and Additional Multi-Site Technical Evaluation of OGM
Rhea-AI Summary
Bionano Laboratories (BNGO) announced the publication of a study covering the analytical validation of its laboratory developed test (LDT), OGM-Dx™ HemeOne, based on optical genome mapping (OGM) analysis of blood or bone marrow samples to detect structural variants in individuals with hematological malignancies. The study demonstrated 100% concordance with traditional methods, 100% specificity and sensitivity for detecting Tier 1 and Tier 2 variants, and identified additional pathogenic variants in 28% of cases. The OGM workflow also showed reproducible concordant performance of 96.4% across all sites.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
none
-
News
Bionano Announces Presentations Featuring OGM Utility Across Blood Cancer Research at the American Society of Hematology (ASH) Annual Meeting
Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) announced that the American Society of Hematology (ASH) Annual Meeting and Exposition 2023 will feature a broad range of content covering optical genome mapping's (OGM) utility for research in myeloid cancer, hematological malignancy, leukemia, and blood disorders. Dr. Enze Liu will present findings from a study on the use of OGM to detect structural variants in multiple myeloma. The ASH conference will be held December 9-12, 2023, in San Diego, California and online.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
none
News
Study Shows that OGM Plays an Important Role in Efficient Diagnosis of FSHD
Rhea-AI Summary
Bionano Laboratories (BNGO) announced the largest peer-reviewed study on the use of optical genome mapping (OGM) to diagnose facioscapulohumeral muscular dystrophy (FSHD). The study showed that the OGM-based laboratory developed test (LDT) was 100% accurate and precise when compared to the prior standard, Southern blot analysis. OGM identified 56% of FSHD1 cases and detected mosaic alleles in 3% of samples. The overall diagnostic yield of OGM and NGS combined was 58%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
none
Stock BNGO logo
Bionano Genomics Inc

Nasdaq:BNGO

BNGO Rankings

#4757 Ranked by Market Cap
#5501 Ranked by Stock Gains
N/A Ranked by Dividends

BNGO Stock Data

52.38M
54.49M
0.5%
11.91%
9.64%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
US
San Diego

About BNGO

at bionano genomics®, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. our team is not afraid to venture into uncharted territory to look for answers. we welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home. our next-generation genome mapping and analysis tools help researchers see true genome structure to fill in what’s missing from sequencing-based data. saphyr™, our high-speed, high-throughput whole genome mapping solution, offers unmatched structural variation discovery capabilities and the ability to construct the most complete genome assemblies. at bionano, we are invested in the success of our customers and users around the world, and are dedicated to supporting them with the tools, resources and support they need to achieve their goals and make a real impact on improving quality o